Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Norovirus Interacts with Gut Bacteria to Establish a Persistent Infection That Can Be Blocked by Interferon Lambda

By LabMedica International staff writers
Posted on 27 Jan 2015
A team of molecular microbiologists and virologists has found that norovirus requires an intimate interaction with certain gut bacteria to establish a persistent infection, and that the infective process can be blocked by the immune factor interferon lambda (INFlambda).

Norovirus causes more than 90% of global epidemic nonbacterial gastroenteritis, and it is thought to be spread by a subset of people who maintain a low-level persistent infection. More...
How the enteric virus establishes such persistent infections is not well understood.

Investigators at Washington University School of Medicine (St. Louis, MO, USA) have turned up some interesting new insights regarding how norovirus infection becomes established and is maintained. They reported in the November 27, 2014, online edition of the journal Science that establishment of the viral infection in a mouse model depended on interaction with certain gut bacteria and that the infection could be prevented by treatment with antibiotics. Viral infection could be established following replenishment of the bacterial microbiota. Antibiotics did not prevent tissue infection or affect systemic viral replication, but acted specifically in the intestine.

In a second paper in the same issue of the journal Science, the investigators reported that while the cytokines interferon alpha (IFNalpha) and interferon beta (IFNbeta) prevented the systemic spread of norovirus in the mouse model, only IFNlambda controlled persistent enteric infection. Infection-dependent induction of IFNlambda was governed by the viral capsid protein and correlated with diminished enteric persistence. Treatment of established infection with IFNlambda cured mice in a manner that required non-hematopoietic cell expression of the IFNlambda receptor, Ifnlr1, and was independent of adaptive immunity.

“I believe that is a new concept in immunology,” said senior author Dr. Herbert W. Virgin, professor of pathology and immunology at Washington University School of Medicine. “We thought that interferon lambda and other related molecules in the immune system could only contain viral infections until other parts of the immune system, including antibodies and T-cells, finished the job.”

“The virus actually requires the bacteria to create a persistent infection,” said Dr. Virgin. “The virus appears to have a symbiotic relationship with the bacteria — they share the job of establishing persistence. We need a much more detailed understanding of how antibiotic treatment affects the links among host, bacteria, and virus.”

Related Links:

Washington University School of Medicine



Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Chromogenic Culture System
InTray™ COLOREX™ ECC
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.